| CAS NO: | 170449-18-0 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 5mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| Cas No. | 170449-18-0 |
| 别名 | N-(3-氯苯基)-6,7-二甲氧基-4-喹唑啉胺盐酸盐,Tyrphostin AG-1478 hydrochloride; NSC 693255 hydrochloride |
| Canonical SMILES | ClC1=CC(NC2=NC=NC3=C2C=C(OC)C(OC)=C3)=CC=C1.Cl |
| 分子式 | C16H14ClN3O2.HCl |
| 分子量 | 352.22 |
| 溶解度 | Soluble in DMSO |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Potent and selective inhibitor of epidermal growth factor receptor kinase (IC50 values 3 nM for EGFR and > 100 μM for ErbB2 and PDGFR). Inhibits proliferation of NCI-H2170 NSCLC cells in vitro (IC50 = 1 μM). Eguchi et al (1998) Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. J.Biol.Chem. 273 8890 PMID:9535870 |Han et al (1996) Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors. Cancer Res. 56 3859 PMID:8752145 |Puri and Salgia (2008) Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J.Carcinog. 7 9 PMID:19240370 |Levitzki and Gazit (1995) Tyrosine kinase inhibition: an approach to drug development. Science 267 1782 PMID:7892601 |
m.cnreagent.com